Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges

Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 14; no. 17; p. 4160
Main Authors Zhao, Yueshui, Deng, Jian, Rao, Shuangfeng, Guo, Sipeng, Shen, Jing, Du, Fukuan, Wu, Xu, Chen, Yu, Li, Mingxing, Chen, Meijuan, Li, Xiaobing, Li, Wanping, Gu, Li, Sun, Yuhong, Zhang, Zhuo, Wen, Qinglian, Xiao, Zhangang, Li, Jing
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 27.08.2022
MDPI
Subjects
Antigens
Awards & honors
Breast cancer
Cancer
Care and treatment
Cervical cancer
Cholangiocarcinoma
Clinical trials
Colorectal cancer
Drug dosages
Health aspects
Human papillomavirus
Immunotherapy
Interleukin 2
Lymphocytes
Medical research
Melanoma
Metastasis
Microenvironments
Patients
Response rates
Review
Solid tumors
Toxicity
Tumor cells
Tumor-infiltrating lymphocytes
Tumors
China
Online AccessGet full text

Cover

Abstract Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.
AbstractList Simple SummaryOver the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumor lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have improved. Clinical use of TILs for solid tumor treatment showed good efficacy. In this review, we summarize the current strategies and challenges of TIL generation. We highlight the clinical trials where TIL therapy is used independently and in combination with other therapies for solid tumor treatment. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.AbstractOver the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.
Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumor lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have improved. Clinical use of TILs for solid tumor treatment showed good efficacy. In this review, we summarize the current strategies and challenges of TIL generation. We highlight the clinical trials where TIL therapy is used independently and in combination with other therapies for solid tumor treatment. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed. Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient's own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.
Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient's own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient's own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.
Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumor lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have improved. Clinical use of TILs for solid tumor treatment showed good efficacy. In this review, we summarize the current strategies and challenges of TIL generation. We highlight the clinical trials where TIL therapy is used independently and in combination with other therapies for solid tumor treatment. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.
Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s own immune cells from the microenvironment of the solid tumor to kill tumor cells. In this review, we provide a comprehensive summary of the current strategies and challenges in TIL isolation and generation. Moreover, the current clinical experience of TIL therapy is summarized and discussed, with an emphasis on lymphodepletion regimen, the use of interleukin-2, and related toxicity. Furthermore, we highlight the clinical trials where TIL therapy is used independently and in combination with other types of therapy for solid cancers. Finally, the limitations, future potential, and directions of TIL therapy for solid tumor treatment are also discussed.
Audience Academic
Author Sun, Yuhong
Li, Mingxing
Li, Jing
Chen, Yu
Li, Xiaobing
Du, Fukuan
Gu, Li
Rao, Shuangfeng
Wu, Xu
Shen, Jing
Li, Wanping
Xiao, Zhangang
Zhao, Yueshui
Zhang, Zhuo
Deng, Jian
Guo, Sipeng
Chen, Meijuan
Wen, Qinglian
AuthorAffiliation 4 Department of Pharmacy, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, China
6 Department of Oncology and Hematology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, China
1 Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China
3 South Sichuan Institute of Translational Medicine, Luzhou 646000, China
2 Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China
5 Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China
AuthorAffiliation_xml – name: 6 Department of Oncology and Hematology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, China
– name: 2 Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Southwest Medical University, Luzhou 646000, China
– name: 3 South Sichuan Institute of Translational Medicine, Luzhou 646000, China
– name: 5 Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, China
– name: 1 Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China
– name: 4 Department of Pharmacy, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou 646000, China
Author_xml – sequence: 1
  givenname: Yueshui
  orcidid: 0000-0002-1972-6130
  surname: Zhao
  fullname: Zhao, Yueshui
– sequence: 2
  givenname: Jian
  surname: Deng
  fullname: Deng, Jian
– sequence: 3
  givenname: Shuangfeng
  surname: Rao
  fullname: Rao, Shuangfeng
– sequence: 4
  givenname: Sipeng
  surname: Guo
  fullname: Guo, Sipeng
– sequence: 5
  givenname: Jing
  surname: Shen
  fullname: Shen, Jing
– sequence: 6
  givenname: Fukuan
  surname: Du
  fullname: Du, Fukuan
– sequence: 7
  givenname: Xu
  surname: Wu
  fullname: Wu, Xu
– sequence: 8
  givenname: Yu
  surname: Chen
  fullname: Chen, Yu
– sequence: 9
  givenname: Mingxing
  surname: Li
  fullname: Li, Mingxing
– sequence: 10
  givenname: Meijuan
  surname: Chen
  fullname: Chen, Meijuan
– sequence: 11
  givenname: Xiaobing
  surname: Li
  fullname: Li, Xiaobing
– sequence: 12
  givenname: Wanping
  surname: Li
  fullname: Li, Wanping
– sequence: 13
  givenname: Li
  surname: Gu
  fullname: Gu, Li
– sequence: 14
  givenname: Yuhong
  surname: Sun
  fullname: Sun, Yuhong
– sequence: 15
  givenname: Zhuo
  surname: Zhang
  fullname: Zhang, Zhuo
– sequence: 16
  givenname: Qinglian
  surname: Wen
  fullname: Wen, Qinglian
– sequence: 17
  givenname: Zhangang
  surname: Xiao
  fullname: Xiao, Zhangang
– sequence: 18
  givenname: Jing
  surname: Li
  fullname: Li, Jing
BookMark eNp1ks1rFDEYxoO02Fp79jrgpR62zXc6HoSyaF1YUHA8h0zmndmUTLImM8L-92bZiu1ik8MbyO95kjdP3qCTEAMg9I7ga8ZqfGNNsJAy4URxIvErdE6xogspa37yZH2GLnN-wGUwRpRUr9EZk1gpWctz1DbzGFO1Cr3zUzKTC0O13o3bTbS7CaqrZrX-UDUbSGa7q_pC_ojeddVB1SQw0whh-lh9T3FIkLOLIVcmdNVyY7yHMEB-i0574zNcPtYL9PPL52b5dbH-dr9a3q0XVjAyLbpOEoVxZ4lRgikLXLSMcStKIZIR3Mue8VYUzKpO1mCVYtLSjrRtLXnPLtCng-92bkfobLlXMl5vkxtN2ulonH6-E9xGD_G3rrkQmNwWg6tHgxR_zZAnPbpswXsTIM5ZU0XorZC0pgV9f4Q-xDmF0t6eIlQwSvk_ajAetAt9LOfavam-U1wUssRQqOv_UGV2MDpbIi_RwHOBOAhsijkn6LV1U4ku7ttyXhOs9_9DH_2Pors50v19m5cUfwDrJb5A
CitedBy_id crossref_primary_10_1016_j_jep_2024_117733
crossref_primary_10_1016_j_intimp_2023_110981
crossref_primary_10_1038_s41422_023_00871_7
crossref_primary_10_1016_j_intimp_2023_110062
crossref_primary_10_1002_jgm_70000
crossref_primary_10_2147_IJN_S455213
crossref_primary_10_1038_s41401_024_01355_z
crossref_primary_10_1039_D4NR01740D
crossref_primary_10_1177_17588359241302021
crossref_primary_10_3390_cells13050451
crossref_primary_10_1007_s40291_024_00708_y
crossref_primary_10_3389_fimmu_2025_1537947
crossref_primary_10_47183_mes_2024_26_4_87_97
crossref_primary_10_1002_mog2_92
crossref_primary_10_1158_2159_8290_CD_24_0827
crossref_primary_10_1002_pros_24597
crossref_primary_10_1038_s41698_024_00725_4
crossref_primary_10_3390_cimb45110576
crossref_primary_10_1002_bmm2_70003
crossref_primary_10_1007_s00262_024_03793_4
crossref_primary_10_1007_s00761_024_01592_1
crossref_primary_10_1016_j_cdev_2024_203904
crossref_primary_10_3390_jcm13216537
crossref_primary_10_3390_ijms252413569
crossref_primary_10_3390_ijms25179463
crossref_primary_10_1007_s12026_023_09376_2
crossref_primary_10_3389_fimmu_2024_1484535
crossref_primary_10_3390_vaccines11081354
crossref_primary_10_1016_j_soncn_2025_151841
crossref_primary_10_1016_j_mbm_2024_100068
crossref_primary_10_1007_s00018_024_05412_y
crossref_primary_10_7759_cureus_68351
crossref_primary_10_3390_ijms25021266
crossref_primary_10_1016_j_intimp_2023_109882
crossref_primary_10_1186_s12935_024_03628_3
crossref_primary_10_3390_cancers14205168
crossref_primary_10_3389_fonc_2024_1336546
crossref_primary_10_1080_2162402X_2024_2392898
crossref_primary_10_3390_molecules29163891
crossref_primary_10_1007_s12672_024_01410_5
crossref_primary_10_1142_S021833902350047X
crossref_primary_10_1021_acsnano_4c07306
crossref_primary_10_1007_s12672_024_00904_6
crossref_primary_10_3390_biology13050307
crossref_primary_10_3390_biology12111419
crossref_primary_10_1016_j_adcanc_2023_100107
crossref_primary_10_1080_19490976_2024_2341717
crossref_primary_10_3390_ijms26062716
crossref_primary_10_1038_s41577_024_01061_1
crossref_primary_10_3390_cancers15092536
crossref_primary_10_1177_15330338231204198
crossref_primary_10_34133_bmr_0015
crossref_primary_10_1002_mco2_368
crossref_primary_10_1016_j_canlet_2024_217281
crossref_primary_10_1016_j_dld_2024_08_003
crossref_primary_10_1111_imm_13793
crossref_primary_10_3389_fonc_2023_1216829
crossref_primary_10_3390_cancers15082287
crossref_primary_10_1007_s11684_023_1015_9
crossref_primary_10_1007_s12274_022_5254_x
crossref_primary_10_1200_EDBK_431608
crossref_primary_10_1038_s41392_022_01270_x
crossref_primary_10_1007_s40883_024_00338_0
crossref_primary_10_1186_s13046_025_03359_x
crossref_primary_10_1016_j_critrevonc_2025_104671
crossref_primary_10_1080_17425247_2023_2241367
crossref_primary_10_1186_s12964_023_01430_8
crossref_primary_10_3389_fimmu_2024_1354313
crossref_primary_10_1016_j_beha_2025_101600
crossref_primary_10_3390_cancers16050911
crossref_primary_10_1007_s12094_024_03530_4
crossref_primary_10_3390_cancers15143733
crossref_primary_10_3390_vaccines13020128
Cites_doi 10.1097/CJI.0b013e31818403d5
10.1002/med.21727
10.1097/CJI.0b013e3181fad2b0
10.1080/2162402X.2016.1252894
10.4049/jimmunol.0904114
10.1038/s41591-021-01462-y
10.1136/jitc-2020-000848
10.1097/CJI.0000000000000111
10.1158/1078-0432.CCR-13-0380
10.1200/JCO.2016.66.7220
10.1200/JCO.2008.16.5449
10.1158/1078-0432.CCR-10-0041
10.1093/annonc/mdz398
10.1200/JCO.1994.12.7.1475
10.1158/2326-6066.CIR-15-0215
10.1158/2326-6066.CIR-18-0095
10.1038/s41573-019-0038-z
10.1097/00002371-200307000-00005
10.1038/nature22396
10.1136/jitc-2019-000188
10.1158/1078-0432.CCR-15-1879
10.1038/s41590-020-00850-9
10.1126/science.1251102
10.1007/s00262-012-1245-1
10.3389/fimmu.2020.00340
10.1038/s41598-020-60738-4
10.1016/S1470-2045(17)30251-6
10.1126/science.aak9510
10.1007/s00262-019-02307-x
10.1158/1078-0432.CCR-17-0831
10.1371/journal.pone.0013940
10.1371/journal.pone.0051805
10.1158/1078-0432.CCR-18-2722
10.1016/j.cell.2017.01.017
10.1016/j.cell.2016.08.052
10.3389/fimmu.2019.01415
10.1182/blood-2006-11-056168
10.1016/j.molonc.2015.10.018
10.3389/fonc.2018.00044
10.1016/j.trecan.2020.05.009
10.1200/JCO.21.00612
10.1097/CJI.0b013e318177a4ba
10.1038/s41467-018-05072-0
10.1182/blood-2017-12-822569
10.1016/j.ccell.2022.01.002
10.1158/0008-5472.CAN-17-0236
10.1038/s41467-020-18570-x
10.1126/science.3489291
10.1016/j.jbo.2020.100332
10.1126/science.1076514
10.1038/nm.3161
10.3389/fimmu.2017.01211
10.1126/science.aaa4971
10.1080/2162402X.2018.1476816
10.3389/fimmu.2019.00128
10.1097/CJI.0000000000000230
10.1016/j.phrs.2018.08.019
10.1158/2326-6066.CIR-14-0239
10.1097/CJI.0b013e31824e801f
10.1177/0022034519882618
10.1056/NEJMoa1609279
10.1158/1078-0432.CCR-14-1934
10.1158/1078-0432.CCR-16-2680
10.1038/ni.3415
10.1007/s00262-019-02448-z
10.1182/blood-2008-12-195792
10.4161/onci.18851
10.1097/CJI.0b013e318209c94c
10.1093/intimm/dxaa046
10.1097/CJI.0b013e3181b88ffc
10.1186/s40425-016-0164-7
10.1097/CMR.0000000000000214
10.1111/j.1365-3083.2011.02640.x
10.1172/JCI73639
10.3389/fonc.2021.794183
10.18632/oncotarget.23007
10.1200/JCO.2014.58.9093
10.1093/jnci/86.15.1159
10.1089/hum.2007.0171
10.1038/s41467-021-22980-w
10.1016/j.ymthe.2018.06.001
10.1158/1078-0432.CCR-18-0573
10.1007/s00262-015-1691-7
10.1111/j.0105-2896.2006.00391.x
10.1038/s41417-020-0189-4
10.1182/blood-2007-09-113050
10.3389/fimmu.2018.02265
10.1136/jitc-2020-001743
10.1056/NEJM198812223192527
10.1371/journal.pone.0153053
10.1007/s00262-009-0792-6
10.1016/j.cell.2019.03.005
10.1080/14740338.2017.1382472
10.1172/JCI83871
10.1146/annurev-immunol-041015-055318
10.1126/scitranslmed.aav7431
10.1084/jem.20050732
10.1158/2326-6066.CIR-20-0270
10.1002/ajh.25418
10.1097/PPO.0b013e31824d4465
10.1007/978-1-4939-8979-9_7
10.1158/1078-0432.CCR-11-0116
10.1073/pnas.052676899
10.1038/s41586-018-0130-2
10.3389/fimmu.2018.02987
10.4049/jimmunol.174.5.2591
10.1158/1078-0432.CCR-13-0945
10.1189/jlb.0603272
10.1038/s41591-018-0040-8
10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
10.1186/1479-5876-10-169
10.1007/s00262-020-02804-4
10.1158/1078-0432.CCR-16-0906
10.1093/jnci/83.13.932
10.1158/1078-0432.CCR-12-1177
10.1084/jem.155.6.1823
10.4161/onci.26615
10.1158/1078-0432.CCR-10-1297
10.1038/nri1349
10.1158/1535-7163.MCT-14-0290
10.3390/ijms20061483
10.3390/cancers13164129
10.1007/s00262-011-1182-4
10.18632/oncotarget.27604
10.1038/ni.3775
10.1200/JCO.2019.37.15_suppl.2538
10.1056/NEJMoa1112302
ContentType Journal Article
Copyright COPYRIGHT 2022 MDPI AG
2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022 by the authors. 2022
Copyright_xml – notice: COPYRIGHT 2022 MDPI AG
– notice: 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022 by the authors. 2022
DBID AAYXX
CITATION
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.3390/cancers14174160
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
ProQuest SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID PMC9455018
A745271077
10_3390_cancers14174160
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 81972643
– fundername: Luzhou Municipal People’s Government; Southwest Medical University
  grantid: 2019LZXNYDJ45
GroupedDBID ---
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RPM
TUS
PMFND
3V.
7T5
7TO
7XB
8FK
H94
MBDVC
PKEHL
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c531t-dd61700dc1a7537ce45b334c55b316310f6f34b5d61c7d69ec7736c2d1bb964f3
IEDL.DBID M48
ISSN 2072-6694
IngestDate Thu Aug 21 14:34:41 EDT 2025
Fri Jul 11 00:49:24 EDT 2025
Fri Jul 25 12:00:22 EDT 2025
Tue Jun 17 21:43:33 EDT 2025
Tue Jun 10 20:53:11 EDT 2025
Tue Jul 01 01:20:54 EDT 2025
Thu Apr 24 23:01:08 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 17
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c531t-dd61700dc1a7537ce45b334c55b316310f6f34b5d61c7d69ec7736c2d1bb964f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
These authors contributed equally to this work.
ORCID 0000-0002-1972-6130
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/cancers14174160
PMID 36077696
PQID 2711253224
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9455018
proquest_miscellaneous_2712856292
proquest_journals_2711253224
gale_infotracmisc_A745271077
gale_infotracacademiconefile_A745271077
crossref_citationtrail_10_3390_cancers14174160
crossref_primary_10_3390_cancers14174160
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20220827
PublicationDateYYYYMMDD 2022-08-27
PublicationDate_xml – month: 8
  year: 2022
  text: 20220827
  day: 27
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Cancers
PublicationYear 2022
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Kalia (ref_76) 2018; 9
ref_94
Dudley (ref_70) 2008; 26
Robbins (ref_60) 2013; 19
Sharma (ref_22) 2017; 168
Lee (ref_21) 2017; 8
Dudley (ref_66) 2002; 298
Aebersold (ref_30) 1991; 83
Lotze (ref_73) 1981; 41
Peng (ref_100) 2020; 11
Rosenberg (ref_3) 1986; 233
Rosenberg (ref_4) 1988; 319
Ye (ref_53) 2014; 20
Dudley (ref_34) 2010; 16
Chowdhury (ref_92) 2018; 6
Feist (ref_114) 2021; 28
Chandran (ref_14) 2017; 18
Donia (ref_36) 2015; 9
Hossain (ref_127) 2021; 41
Carmona (ref_45) 2020; 11
Lozano (ref_51) 2017; 77
Creelan (ref_11) 2021; 27
Acquavella (ref_83) 2008; 31
Parkhurst (ref_59) 2017; 23
Tran (ref_9) 2014; 344
Subbiah (ref_102) 2020; 6
ref_25
Hofland (ref_123) 2018; 132
Gattinoni (ref_63) 2005; 202
ref_122
Veluchamy (ref_121) 2017; 7
Dudley (ref_24) 2003; 26
Wagner (ref_129) 2019; 177
Kverneland (ref_97) 2020; 11
Simoni (ref_42) 2018; 557
Mackay (ref_95) 2010; 184
Vitale (ref_118) 2019; 10
Marabondo (ref_82) 2017; 16
Yang (ref_90) 2015; 125
Sosman (ref_108) 2012; 366
Hsu (ref_88) 2021; 12
Hall (ref_98) 2016; 4
Ganesan (ref_41) 2017; 18
Salem (ref_64) 2010; 59
Ilieva (ref_106) 2014; 13
Rosenberg (ref_6) 2011; 17
Andersen (ref_86) 2016; 22
Ullenhag (ref_85) 2012; 61
(ref_27) 2019; 1913
Cheng (ref_72) 2002; 99
ref_81
Friese (ref_96) 2020; 10
Sarnaik (ref_15) 2021; 39
Rosenberg (ref_65) 1994; 86
Antony (ref_62) 2005; 174
Xiao (ref_40) 2019; 98
Grimm (ref_74) 1982; 155
Walboomers (ref_19) 1999; 189
Malek (ref_75) 2003; 74
Gros (ref_49) 2014; 124
Sloot (ref_107) 2016; 26
Draper (ref_8) 2015; 33
Santos (ref_113) 2020; 8
Mills (ref_126) 2021; 9
Heemskerk (ref_16) 2020; 8
Zacharakis (ref_7) 2018; 24
Jin (ref_61) 2012; 35
Heemskerk (ref_131) 2008; 19
Dafni (ref_13) 2019; 30
Khammari (ref_115) 2015; 64
Besser (ref_29) 2010; 16
Chacon (ref_57) 2015; 21
Deniger (ref_12) 2018; 24
Gordon (ref_47) 2017; 545
Kvistborg (ref_116) 2012; 1
Hinrichs (ref_78) 2008; 111
Schumacher (ref_117) 2015; 348
Klebanoff (ref_37) 2006; 211
Jazaeri (ref_18) 2019; 37
Kortekaas (ref_44) 2020; 8
Liu (ref_80) 2017; 6
Sapoznik (ref_130) 2012; 61
Meng (ref_79) 2016; 39
Prickett (ref_56) 2016; 4
Goff (ref_68) 2016; 34
Itzhaki (ref_55) 2017; 8
Donia (ref_33) 2012; 75
Wang (ref_89) 2020; 25
Besser (ref_5) 2013; 19
Santos (ref_71) 2018; 26
Liu (ref_77) 2021; 22
Poch (ref_26) 2018; 7
Bloemendal (ref_111) 2018; 9
McLane (ref_93) 2019; 37
Singer (ref_128) 2016; 166
Helman (ref_17) 2019; 25
Cooper (ref_105) 2013; 2
Martinez (ref_125) 2019; 10
Ellebaek (ref_84) 2012; 10
Itzhaki (ref_35) 2011; 34
ref_119
Wu (ref_28) 2012; 18
Tavera (ref_58) 2018; 41
Nissani (ref_69) 2021; 9
Liu (ref_124) 2022; 11
Ahmadzadeh (ref_46) 2009; 114
Peiffer (ref_109) 2021; 70
Deniger (ref_110) 2017; 23
Radvanyi (ref_38) 2012; 18
Duhen (ref_43) 2018; 9
Sebestyen (ref_120) 2020; 19
Wrzesinski (ref_67) 2010; 33
Schwartzentruber (ref_31) 1994; 12
Webb (ref_39) 2015; 3
Asrir (ref_132) 2022; 40
Wolfl (ref_52) 2007; 110
Nguyen (ref_87) 2019; 68
Chang (ref_23) 2016; 17
ref_103
Kuske (ref_104) 2018; 136
Mullinax (ref_99) 2018; 8
Spiess (ref_2) 1987; 79
Zhang (ref_112) 2020; 69
Pasetto (ref_20) 2017; 356
Tran (ref_32) 2008; 31
Mayoux (ref_101) 2020; 12
Forget (ref_54) 2017; 23
Feins (ref_1) 2019; 94
Kumar (ref_91) 2021; 33
Tran (ref_10) 2016; 375
Chen (ref_48) 2004; 4
Inozume (ref_50) 2010; 33
References_xml – volume: 31
  start-page: 742
  year: 2008
  ident: ref_32
  article-title: Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e31818403d5
– volume: 41
  start-page: 156
  year: 2021
  ident: ref_127
  article-title: Reinvigorating exhausted CD8(+) cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
  publication-title: Med. Res. Rev.
  doi: 10.1002/med.21727
– volume: 33
  start-page: 956
  year: 2010
  ident: ref_50
  article-title: Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e3181fad2b0
– volume: 6
  start-page: e1252894
  year: 2017
  ident: ref_80
  article-title: Tumor-infiltrating lymphocytes (TILs) from patients with glioma
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2016.1252894
– volume: 184
  start-page: 3442
  year: 2010
  ident: ref_95
  article-title: Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.0904114
– volume: 27
  start-page: 1410
  year: 2021
  ident: ref_11
  article-title: Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: A phase 1 trial
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01462-y
– volume: 8
  start-page: e000848
  year: 2020
  ident: ref_16
  article-title: Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: Boosting of neoantigen-specific T cell reactivity and long-term follow-up
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-000848
– volume: 7
  start-page: e1375641
  year: 2017
  ident: ref_121
  article-title: A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of Vγ9Vδ2-T cells
  publication-title: Oncoimmunology
– volume: 39
  start-page: 81
  year: 2016
  ident: ref_79
  article-title: Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0000000000000111
– volume: 19
  start-page: 4792
  year: 2013
  ident: ref_5
  article-title: Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: Intent-to-treat analysis and efficacy after failure to prior immunotherapies
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-0380
– volume: 34
  start-page: 2389
  year: 2016
  ident: ref_68
  article-title: Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2016.66.7220
– volume: 26
  start-page: 5233
  year: 2008
  ident: ref_70
  article-title: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2008.16.5449
– volume: 16
  start-page: 2646
  year: 2010
  ident: ref_29
  article-title: Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-10-0041
– volume: 30
  start-page: 1902
  year: 2019
  ident: ref_13
  article-title: Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: A systematic review and meta-analysis
  publication-title: Ann. Oncol. Off. J. Eur. Soc. Med. Oncol.
  doi: 10.1093/annonc/mdz398
– volume: 12
  start-page: 1475
  year: 1994
  ident: ref_31
  article-title: In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.1994.12.7.1475
– volume: 4
  start-page: 669
  year: 2016
  ident: ref_56
  article-title: Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-15-0215
– volume: 6
  start-page: 1375
  year: 2018
  ident: ref_92
  article-title: PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti–PD-1 Therapy
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-18-0095
– volume: 19
  start-page: 169
  year: 2020
  ident: ref_120
  article-title: Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-019-0038-z
– volume: 26
  start-page: 332
  year: 2003
  ident: ref_24
  article-title: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients
  publication-title: J. Immunother.
  doi: 10.1097/00002371-200307000-00005
– volume: 545
  start-page: 495
  year: 2017
  ident: ref_47
  article-title: PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
  publication-title: Nature
  doi: 10.1038/nature22396
– volume: 8
  start-page: e000188
  year: 2020
  ident: ref_113
  article-title: Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2019-000188
– volume: 22
  start-page: 3734
  year: 2016
  ident: ref_86
  article-title: Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-15-1879
– volume: 22
  start-page: 358
  year: 2021
  ident: ref_77
  article-title: IL-2 regulates tumor-reactive CD8 T cell exhaustion by activating the aryl hydrocarbon receptor
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-020-00850-9
– volume: 344
  start-page: 641
  year: 2014
  ident: ref_9
  article-title: Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
  publication-title: Science
  doi: 10.1126/science.1251102
– volume: 61
  start-page: 1833
  year: 2012
  ident: ref_130
  article-title: CXCR1 as a novel target for directing reactive T cells toward melanoma: Implications for adoptive cell transfer immunotherapy
  publication-title: Cancer Immunol. Immunother. CII
  doi: 10.1007/s00262-012-1245-1
– volume: 11
  start-page: 340
  year: 2020
  ident: ref_45
  article-title: Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.00340
– volume: 10
  start-page: 3914
  year: 2020
  ident: ref_96
  article-title: CTLA-4 blockade boosts the expansion of tumor-reactive CD8+ tumor-infiltrating lymphocytes in ovarian cancer
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-60738-4
– volume: 18
  start-page: 792
  year: 2017
  ident: ref_14
  article-title: Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: A single-centre, two-stage, single-arm, phase 2 study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30251-6
– volume: 356
  start-page: 200
  year: 2017
  ident: ref_20
  article-title: Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
  publication-title: Science
  doi: 10.1126/science.aak9510
– volume: 68
  start-page: 773
  year: 2019
  ident: ref_87
  article-title: Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-019-02307-x
– volume: 23
  start-page: 7263
  year: 2017
  ident: ref_54
  article-title: 4-1BB Agonist Focuses CD8 Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-0831
– ident: ref_25
  doi: 10.1371/journal.pone.0013940
– ident: ref_122
  doi: 10.1371/journal.pone.0051805
– volume: 25
  start-page: 1486
  year: 2019
  ident: ref_17
  article-title: A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers
  publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-2722
– volume: 168
  start-page: 707
  year: 2017
  ident: ref_22
  article-title: Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
  publication-title: Cell
  doi: 10.1016/j.cell.2017.01.017
– volume: 166
  start-page: 1500
  year: 2016
  ident: ref_128
  article-title: A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T Cells
  publication-title: Cell
  doi: 10.1016/j.cell.2016.08.052
– volume: 10
  start-page: 1415
  year: 2019
  ident: ref_118
  article-title: An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.01415
– volume: 110
  start-page: 201
  year: 2007
  ident: ref_52
  article-title: Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities
  publication-title: Blood
  doi: 10.1182/blood-2006-11-056168
– volume: 9
  start-page: 1918
  year: 2015
  ident: ref_36
  article-title: Tumor-infiltrating lymphocytes for the treatment of metastatic cancer
  publication-title: Mol. Oncol.
  doi: 10.1016/j.molonc.2015.10.018
– volume: 8
  start-page: 44
  year: 2018
  ident: ref_99
  article-title: Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2018.00044
– volume: 6
  start-page: 797
  year: 2020
  ident: ref_102
  article-title: Clinical Development of BRAF plus MEK Inhibitor Combinations
  publication-title: Trends Cancer
  doi: 10.1016/j.trecan.2020.05.009
– volume: 39
  start-page: 2656
  year: 2021
  ident: ref_15
  article-title: Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.21.00612
– volume: 31
  start-page: 569
  year: 2008
  ident: ref_83
  article-title: Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e318177a4ba
– volume: 9
  start-page: 2724
  year: 2018
  ident: ref_43
  article-title: Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-05072-0
– volume: 41
  start-page: 4420
  year: 1981
  ident: ref_73
  article-title: Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor
  publication-title: Cancer Res.
– volume: 132
  start-page: 2260
  year: 2018
  ident: ref_123
  article-title: Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib
  publication-title: Blood
  doi: 10.1182/blood-2017-12-822569
– volume: 40
  start-page: 318
  year: 2022
  ident: ref_132
  article-title: Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2022.01.002
– volume: 77
  start-page: 3672
  year: 2017
  ident: ref_51
  article-title: Expansion of Tumor-Infiltrating CD8(+) T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-17-0236
– volume: 11
  start-page: 4835
  year: 2020
  ident: ref_100
  article-title: PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18570-x
– volume: 233
  start-page: 1318
  year: 1986
  ident: ref_3
  article-title: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
  publication-title: Science
  doi: 10.1126/science.3489291
– volume: 25
  start-page: 100332
  year: 2020
  ident: ref_89
  article-title: Adoptive transfer of TILs plus anti-PD1 therapy: An alternative combination therapy for treating metastatic osteosarcoma
  publication-title: J. Bone Oncol.
  doi: 10.1016/j.jbo.2020.100332
– ident: ref_81
– volume: 298
  start-page: 850
  year: 2002
  ident: ref_66
  article-title: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
  publication-title: Science
  doi: 10.1126/science.1076514
– volume: 19
  start-page: 747
  year: 2013
  ident: ref_60
  article-title: Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
  publication-title: Nat. Med.
  doi: 10.1038/nm.3161
– volume: 8
  start-page: 1211
  year: 2017
  ident: ref_55
  article-title: Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.01211
– volume: 348
  start-page: 69
  year: 2015
  ident: ref_117
  article-title: Neoantigens in cancer immunotherapy
  publication-title: Science
  doi: 10.1126/science.aaa4971
– volume: 7
  start-page: e1476816
  year: 2018
  ident: ref_26
  article-title: Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer
  publication-title: Oncoimmunology
  doi: 10.1080/2162402X.2018.1476816
– volume: 10
  start-page: 128
  year: 2019
  ident: ref_125
  article-title: CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00128
– volume: 41
  start-page: 399
  year: 2018
  ident: ref_58
  article-title: Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0000000000000230
– volume: 136
  start-page: 151
  year: 2018
  ident: ref_104
  article-title: Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2018.08.019
– volume: 3
  start-page: 926
  year: 2015
  ident: ref_39
  article-title: PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0239
– volume: 35
  start-page: 283
  year: 2012
  ident: ref_61
  article-title: Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e31824e801f
– volume: 98
  start-page: 1480
  year: 2019
  ident: ref_40
  article-title: CD103+ T and Dendritic Cells Indicate a Favorable Prognosis in Oral Cancer
  publication-title: J. Dent. Res.
  doi: 10.1177/0022034519882618
– volume: 375
  start-page: 2255
  year: 2016
  ident: ref_10
  article-title: T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1609279
– volume: 21
  start-page: 611
  year: 2015
  ident: ref_57
  article-title: Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-1934
– volume: 23
  start-page: 2491
  year: 2017
  ident: ref_59
  article-title: Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-2680
– volume: 17
  start-page: 364
  year: 2016
  ident: ref_23
  article-title: Emerging concepts of T cell metabolism as a target of immunotherapy
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3415
– volume: 69
  start-page: 135
  year: 2020
  ident: ref_112
  article-title: Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
  publication-title: Cancer Immunol. Immunother. CII
  doi: 10.1007/s00262-019-02448-z
– volume: 114
  start-page: 1537
  year: 2009
  ident: ref_46
  article-title: Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
  publication-title: Blood
  doi: 10.1182/blood-2008-12-195792
– volume: 1
  start-page: 409
  year: 2012
  ident: ref_116
  article-title: TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients
  publication-title: Oncoimmunology
  doi: 10.4161/onci.18851
– volume: 34
  start-page: 212
  year: 2011
  ident: ref_35
  article-title: Establishment and large-scale expansion of minimally cultured “young” tumor infiltrating lymphocytes for adoptive transfer therapy
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e318209c94c
– volume: 33
  start-page: 17
  year: 2021
  ident: ref_91
  article-title: Immune metabolism in PD-1 blockade-based cancer immunotherapy
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxaa046
– volume: 33
  start-page: 1
  year: 2010
  ident: ref_67
  article-title: Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells
  publication-title: J. Immunother.
  doi: 10.1097/CJI.0b013e3181b88ffc
– volume: 4
  start-page: 61
  year: 2016
  ident: ref_98
  article-title: Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-016-0164-7
– volume: 26
  start-page: 83
  year: 2016
  ident: ref_107
  article-title: BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: A potential neoadjuvant strategy
  publication-title: Melanoma Res.
  doi: 10.1097/CMR.0000000000000214
– volume: 75
  start-page: 157
  year: 2012
  ident: ref_33
  article-title: Characterization and comparison of ‘standard’ and ‘young’ tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution
  publication-title: Scand. J. Immunol.
  doi: 10.1111/j.1365-3083.2011.02640.x
– volume: 124
  start-page: 2246
  year: 2014
  ident: ref_49
  article-title: PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI73639
– volume: 11
  start-page: 794183
  year: 2022
  ident: ref_124
  article-title: TCR-T Immunotherapy: The Challenges and Solutions
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2021.794183
– volume: 8
  start-page: 113345
  year: 2017
  ident: ref_21
  article-title: Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.23007
– volume: 33
  start-page: 1543
  year: 2015
  ident: ref_8
  article-title: Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells
  publication-title: J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.
  doi: 10.1200/JCO.2014.58.9093
– volume: 86
  start-page: 1159
  year: 1994
  ident: ref_65
  article-title: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/86.15.1159
– volume: 19
  start-page: 496
  year: 2008
  ident: ref_131
  article-title: Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2
  publication-title: Hum. Gene Ther.
  doi: 10.1089/hum.2007.0171
– volume: 12
  start-page: 2768
  year: 2021
  ident: ref_88
  article-title: A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-22980-w
– volume: 26
  start-page: 2243
  year: 2018
  ident: ref_71
  article-title: Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy
  publication-title: Mol. Ther.
  doi: 10.1016/j.ymthe.2018.06.001
– volume: 24
  start-page: 5562
  year: 2018
  ident: ref_12
  article-title: T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-0573
– volume: 64
  start-page: 805
  year: 2015
  ident: ref_115
  article-title: Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients
  publication-title: Cancer Immunol. Immunother. CII
  doi: 10.1007/s00262-015-1691-7
– volume: 211
  start-page: 214
  year: 2006
  ident: ref_37
  article-title: CD8+ T-cell memory in tumor immunology and immunotherapy
  publication-title: Immunol. Rev.
  doi: 10.1111/j.0105-2896.2006.00391.x
– volume: 28
  start-page: 98
  year: 2021
  ident: ref_114
  article-title: Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy
  publication-title: Cancer Gene Ther.
  doi: 10.1038/s41417-020-0189-4
– volume: 111
  start-page: 5326
  year: 2008
  ident: ref_78
  article-title: IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy
  publication-title: Blood
  doi: 10.1182/blood-2007-09-113050
– volume: 9
  start-page: 2265
  year: 2018
  ident: ref_111
  article-title: Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.02265
– volume: 9
  start-page: e001743
  year: 2021
  ident: ref_69
  article-title: Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2020-001743
– volume: 9
  start-page: 25151355211017119
  year: 2021
  ident: ref_126
  article-title: Generating CAR T cells from tumor-infiltrating lymphocytes
  publication-title: Ther. Adv. Vaccines Immunother.
– volume: 319
  start-page: 1676
  year: 1988
  ident: ref_4
  article-title: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJM198812223192527
– ident: ref_94
  doi: 10.1371/journal.pone.0153053
– volume: 59
  start-page: 341
  year: 2010
  ident: ref_64
  article-title: Dendritic cell recovery post-lymphodepletion: A potential mechanism for anti-cancer adoptive T cell therapy and vaccination
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-009-0792-6
– volume: 177
  start-page: 1330
  year: 2019
  ident: ref_129
  article-title: A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer
  publication-title: Cell
  doi: 10.1016/j.cell.2019.03.005
– volume: 16
  start-page: 1347
  year: 2017
  ident: ref_82
  article-title: High-dose interleukin-2 (IL-2) for the treatment of melanoma: Safety considerations and future directions
  publication-title: Expert Opin. Drug. Saf.
  doi: 10.1080/14740338.2017.1382472
– volume: 125
  start-page: 3335
  year: 2015
  ident: ref_90
  article-title: Cancer immunotherapy: Harnessing the immune system to battle cancer
  publication-title: J. Clin. Investig.
  doi: 10.1172/JCI83871
– volume: 37
  start-page: 457
  year: 2019
  ident: ref_93
  article-title: CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer
  publication-title: Annu. Rev. Immunol.
  doi: 10.1146/annurev-immunol-041015-055318
– volume: 12
  start-page: eaav7431
  year: 2020
  ident: ref_101
  article-title: Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aav7431
– volume: 202
  start-page: 907
  year: 2005
  ident: ref_63
  article-title: Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20050732
– volume: 8
  start-page: 1311
  year: 2020
  ident: ref_44
  article-title: CD39 Identifies the CD4 Tumor-Specific T-cell Population in Human Cancer
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-20-0270
– volume: 94
  start-page: S3
  year: 2019
  ident: ref_1
  article-title: An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer
  publication-title: Am. J. Hematol.
  doi: 10.1002/ajh.25418
– volume: 18
  start-page: 160
  year: 2012
  ident: ref_28
  article-title: Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: Current status and future outlook
  publication-title: Cancer J.
  doi: 10.1097/PPO.0b013e31824d4465
– volume: 1913
  start-page: 105
  year: 2019
  ident: ref_27
  article-title: Expansion of Tumor-Infiltrating Lymphocytes from Melanoma Tumors
  publication-title: Methods Mol. Biol.
  doi: 10.1007/978-1-4939-8979-9_7
– volume: 17
  start-page: 4550
  year: 2011
  ident: ref_6
  article-title: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-0116
– volume: 99
  start-page: 3001
  year: 2002
  ident: ref_72
  article-title: Enhanced signaling through the IL-2 receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.052676899
– volume: 557
  start-page: 575
  year: 2018
  ident: ref_42
  article-title: Bystander CD8 T cells are abundant and phenotypically distinct in human tumour infiltrates
  publication-title: Nature
  doi: 10.1038/s41586-018-0130-2
– volume: 9
  start-page: 2987
  year: 2018
  ident: ref_76
  article-title: Regulation of Effector and Memory CD8 T Cell Differentiation by IL-2-A Balancing Act
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.02987
– volume: 174
  start-page: 2591
  year: 2005
  ident: ref_62
  article-title: CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.174.5.2591
– volume: 20
  start-page: 44
  year: 2014
  ident: ref_53
  article-title: CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-13-0945
– volume: 74
  start-page: 961
  year: 2003
  ident: ref_75
  article-title: The main function of IL-2 is to promote the development of T regulatory cells
  publication-title: J. Leukoc. Biol.
  doi: 10.1189/jlb.0603272
– volume: 79
  start-page: 1067
  year: 1987
  ident: ref_2
  article-title: In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2
  publication-title: J. Natl. Cancer Inst.
– volume: 24
  start-page: 724
  year: 2018
  ident: ref_7
  article-title: Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0040-8
– volume: 189
  start-page: 12
  year: 1999
  ident: ref_19
  article-title: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
  publication-title: J. Pathol.
  doi: 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
– volume: 10
  start-page: 169
  year: 2012
  ident: ref_84
  article-title: Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients
  publication-title: J. Transl. Med.
  doi: 10.1186/1479-5876-10-169
– volume: 70
  start-page: 1635
  year: 2021
  ident: ref_109
  article-title: BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
  publication-title: Cancer Immunol. Immunother. CII
  doi: 10.1007/s00262-020-02804-4
– volume: 23
  start-page: 351
  year: 2017
  ident: ref_110
  article-title: A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma
  publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.
  doi: 10.1158/1078-0432.CCR-16-0906
– volume: 83
  start-page: 932
  year: 1991
  ident: ref_30
  article-title: Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: Association with clinical response
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/83.13.932
– volume: 18
  start-page: 6758
  year: 2012
  ident: ref_38
  article-title: Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-12-1177
– volume: 155
  start-page: 1823
  year: 1982
  ident: ref_74
  article-title: Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.155.6.1823
– volume: 2
  start-page: e26615
  year: 2013
  ident: ref_105
  article-title: BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes
  publication-title: Oncoimmunology
  doi: 10.4161/onci.26615
– volume: 16
  start-page: 6122
  year: 2010
  ident: ref_34
  article-title: CD8+ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-10-1297
– volume: 4
  start-page: 336
  year: 2004
  ident: ref_48
  article-title: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri1349
– volume: 13
  start-page: 2769
  year: 2014
  ident: ref_106
  article-title: Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-14-0290
– ident: ref_103
  doi: 10.3390/ijms20061483
– ident: ref_119
  doi: 10.3390/cancers13164129
– volume: 61
  start-page: 725
  year: 2012
  ident: ref_85
  article-title: Adoptive T-cell therapy for malignant melanoma patients with TILs obtained by ultrasound-guided needle biopsy
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-011-1182-4
– volume: 11
  start-page: 2092
  year: 2020
  ident: ref_97
  article-title: Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.27604
– volume: 18
  start-page: 940
  year: 2017
  ident: ref_41
  article-title: Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.3775
– volume: 37
  start-page: 2538
  year: 2019
  ident: ref_18
  article-title: Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2019.37.15_suppl.2538
– volume: 366
  start-page: 707
  year: 2012
  ident: ref_108
  article-title: Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1112302
SSID ssj0000331767
Score 2.5767937
SecondaryResourceType review_article
Snippet Over the past decade, immunotherapy, especially cell-based immunotherapy, has provided new strategies for cancer therapy. Recent clinical studies demonstrated...
Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of...
Simple SummaryOver the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are...
SourceID pubmedcentral
proquest
gale
crossref
SourceType Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 4160
SubjectTerms Antigens
Awards & honors
Breast cancer
Cancer
Care and treatment
Cervical cancer
Cholangiocarcinoma
Clinical trials
Colorectal cancer
Drug dosages
Health aspects
Human papillomavirus
Immunotherapy
Interleukin 2
Lymphocytes
Medical research
Melanoma
Metastasis
Microenvironments
Patients
Response rates
Review
Solid tumors
Toxicity
Tumor cells
Tumor-infiltrating lymphocytes
Tumors
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwEB7BVkJcEOUhAqUyEhLlEJqHEydcUFu1alFbVZBKvUXx2IGVlqRsdg_998xsnKVZCU452E6ieXs8_gbgvc3qxBilfUvOwOfG234eo_QjTDS3PJLWcGrg4jI9vZZfb5Ibl3DrXFnlYBNXhtq0yDny_UhRZJCQ-Mkvt7997hrFp6uuhcZD2CITnGUT2Do8vrz6ts6yBDH5x1T1mD4x7e_3kYk570IZciwSjNzRplHeLJS853lOnsITFzKKg57H2_DANs_g0YU7FH8Oulj-aufirKmnsxUIbvNDnN8Rl1q8W1ixV5ydfxRFjx4gKEYV39vZ1Ih-VTEUmn8WV1yq1cN0dKJqjDgaGq10L-D65Lg4OvVd6wQfSakWvjEMtB4YDCvajyi0MtFxLDGhB0VgYVCndSx1QtNQmTS3qFScYmRCrfNU1vFLmDRtY1-BqJCDwipS2tQSM1J4stXGBpXKUp2ryoNPAwVLdLji3N5iVtL-gklebpDcg731gtseUuPfUz8wS0pWNnonVu7OAP0Zw1aVB0omJBiBUh7sjGaSkuB4eGBq6ZS0K_-KlAfv1sO8kgvPGtsuV3OijGLEPPJAjYRh_e8M0D0eaaY_V0DdOV8ZD7PX___4G3gc8Z2KgEyW2oHJYr60bynSWehdJ85_AInhASQ
  priority: 102
  providerName: ProQuest
Title Tumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
URI https://www.proquest.com/docview/2711253224
https://www.proquest.com/docview/2712856292
https://pubmed.ncbi.nlm.nih.gov/PMC9455018
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9RAEB-0BfGlVKuYth4rCPUlNdlsskmhSC2ttfRK0Tu4ByFkP6IH16S9D-j9987k4zRH9SkPOxuW2d2Z3yS7vx_AexvnoTFSuRaTgUvC224SaOFyHSqSPBLW0KeB_nV0MRSXo3D0Rw6oceDs0dKO9KSG08nhw_3yE274Y6o4sWT_qMk_05kvfIIXWL9vYlqSJGfQb7B-FZYDTJWVoiz3JHejKBE11c9j7-hkqfVYvX5-8q-EdL4NWw2SZCf11L-AJ7Z4Cc_6zb_yHfgxWNyWU_a1yMeTihu3-Mmuljh5pV7OLRvUdAIMQSv7Xk7GhtX2g_bk-RG7obNbNW_HjGWFYaet8srsFQzPzwanF26jpeBq3GVz1xhiXveM9jMsUKS2IlRBIHSID4RkvpdHeSBUiGZamiixWsog0tz4SiWRyIPXsFGUhX0DLNOEEjMulcmFjjECYPA21stkHKlEZg4ctr5LdUM0TnoXkxQLDnJ2uuZsBz6sOtzVHBv_Nj2gyUhpPeA7ddZcIsCREY9VeiJFyBE0SenAfscSd43uNrfTmbaLLsUmxHsY4oQD71bN1JNOohW2XFQ2PEbQmHAHZGcZrMZOjN3dlmL8q2LuTugOuR_v_n9se_Cc0yULD2OY3IeN-XRh3yL0masebH4-u7751oOnX0Z-r1rgvwEOGwZz
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VVIJeEE9hKLBIIMrBrR9rr42EUCmtEppEFbhSb8b7cIkU7BInQvlT_EZmYjvgSHDryYfd9WP325lv17PfALw0UR5oLaRt0BnYlHjbjn3FbU8FklIecaNpa2A0Dvvn_NNFcLEFv9qzMBRW2drElaHWpaI98gNPIDMIEH78_dUPm7JG0d_VNoVGDYtTs_yJS7bq3eAjju8rzzs5To76dpNVwFaIt7mtNWmQO1q5GVJ1oQwPpO9zFeAFyYnr5GHucxlgNSV0GBslhB8qT7tSxiHPfbzvDdjmPn5JD7Y_HI_PPq93dRwf_XEoag0h34-dA0WDN6tc7hL3cTrub9MJbAZm_uXpTu7A7YaissMaU3dhyxT34Oao-Ql_H2Sy-F7O2KDIJ9OV6G5xyYZLREWplnPD9pLB8A1LarUChpyYfSmnE83qVkkb2P6WnVFoWC0LUrGs0OyoTexSPYDza-nUh9ArysI8ApYpIqGZJ6TOuYrQwKBv0MbJRBTKWGQW7Lc9mKpGx5zSaUxTXM9Ql6cbXW7B3rrBVS3h8e-qr2lIUprceE-VNWcU8M1IJis9FDxAIDpCWLDbqYmTUnWL20FNG6NQpX8gbMGLdTG1pEC3wpSLVR0vQk4aexaIDhjW706C4N2SYvJtJQwe0xF1N3r8_4c_h1v9ZDRMh4Px6RPY8eg8h4PmUuxCbz5bmKfIsubyWQNtBl-vezb9Bp_6PVE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anTTxgriKwAAjgRgPobk4cYKE0NhWrayrKsikvYX4EqhUktG0Qv1r_DrOaZJCKsHbnvJgO4nsz-d8to-_A_DCRHmgtZC2QWdgU-JtO_YVtz0VSEp5xI2mrYHzcXh6wT9eBpc78Ku9C0Nhla1NXBtqXSraI-97AplBgPDj_bwJi5gcD95f_bApgxSdtLbpNGqInJnVT1y-Ve-GxzjWLz1vcJIcndpNhgFbIfYWttakR-5o5WZI24UyPJC-z1WADyQqrpOHuc9lgNWU0GFslBB-qDztShmHPPfxvTdgV9CqqAe7H07Gk0-bHR7HR98cilpPyPdjp69oIOeVy13iQU7HFW47hO0gzb-83uA23GroKjus8XUHdkxxF_bOmwP5eyCT5fdyzoZFPp2tBXiLr2y0QoSUarUw7CAZjl6zpFYuYMiP2edyNtWsbpW0Qe5v2YTCxGqJkIplhWZHbZKX6j5cXEunPoBeURbmIbBMESHNPCF1zlWExgb9hDZOJqJQxiKz4E3bg6lqNM0ptcYsxbUNdXm61eUWHGwaXNVyHv-u-oqGJKWJju9UWXNfAf-MJLPSQ8EDBKUjhAX7nZo4QVW3uB3UtDEQVfoHzhY83xRTSwp6K0y5XNfxIuSnsWeB6IBh8-8kDt4tKabf1iLhMV1Xd6NH___4M9jDWZSOhuOzx3DTo6sdDlpOsQ-9xXxpniDhWsinDbIZfLnuyfQbJklBhg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor+Infiltrating+Lymphocyte+Therapy+for+Solid+Tumor+Treatment%3A+Progressions+and+Challenges&rft.jtitle=Cancers&rft.au=Zhao%2C+Yueshui&rft.au=Deng%2C+Jian&rft.au=Rao%2C+Shuangfeng&rft.au=Guo%2C+Sipeng&rft.date=2022-08-27&rft.pub=MDPI+AG&rft.issn=2072-6694&rft.eissn=2072-6694&rft.volume=14&rft.issue=17&rft_id=info:doi/10.3390%2Fcancers14174160&rft.externalDocID=A745271077
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon